CD274 and breast carcinoma: Furthermore, by comparing the pathway of anti-PD-L1 treatment non-responders with baseline in the 4T1 breast cancer mouse model from TISMO (http://tismo.cistrome.org/)32 (Supplementary Fig. 1a–e), we found that several of these post-translational modification pathways were upregulated, implying that post-translational modifications of PD-L1 might be a feature of tumors and promising target for immunotherapy.